Trial of CF101 to Treat Patients With Psoriasis

Exclusion Criteria

• •Erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis
• •Treatment with systemic retinoids, corticosteroids, or immunosuppressive agents within 4 weeks of the Baseline visit
• •Treatment with high potency topical corticosteroids, keratolytics, or coal tar within 2 weeks of the Baseline visit
• •Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit
• •Treatment with a biological agent within a period of time equal to 5 times its circulating half-life
• •Treatment with lithium, hydroxychloroquine or chloroquine within 2 weeks of the Baseline visit
• •Serum creatinine level greater than 1.5 times the laboratory's upper limit of normal
• •Liver aminotransferase levels greater than the laboratory's upper limit of normal
• •Significant acute or chronic medical or psychiatric illness
• •Participation in another investigational drug or vaccine trial concurrently or within 30 days prior to Screening visit.